Previous 10 | Next 10 |
MiRagen Therapeutics (MGEN) shoots 156% premarket after completing the acquisition of privately held Viridian Therapeutics in a stock-for-stock transaction.All of Viridian’s outstanding equity interests were exchanged for a combination of miRagen common stock and Series ...
Acquisition includes clinical stage anti-IGF - 1R monoclonal antibody, VRDN-001 , intended for the treatment of thyroid eye disease (TED) Company plans to use p rivate placement financing p roceeds of $ 91 million to advance mu...
Looking For Penny Stocks On Robinhood? 4 To Watch This Week Whether you’re looking for penny stocks on Robinhood , Webull, TD, Etrade, Interactive Brokers, or any of the other online trading platforms, the goal’s the same. Make money then repeat the process. That might...
Preliminary data from a Phase 2 clinical trial, SOLAR, evaluating miRagen Therapeutics' (MGEN) cobomarsen in patients with cutaneous T-cell lymphoma ((CTCL)) failed to demonstrate a likelihood that the study would achieve the primary endpoint of objective skin response of at least four months...
BOULDER, Colo., Oct. 05, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that it has conducted an internal review of preliminary topline data fr...
miRagen Therapeutics (NASDAQ: MGEN ) has appointed Lee Rauch, as President, Chief Executive Officer and a Director, following the resignation of William Marshall, though he has agreed to act as Senior Technical Advisor. More news on: Miragen Therapeutics, Inc., Healthcare sto...
Lee Rauch appointed President and CEO, following resignation by William Marshall miRagen will undertake an in-depth review of its portfolio Ladenburg Thalmann engaged as financial advisor BOULDER, Colo., Sept. 14, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGE...
BOULDER, Colo., Aug. 20, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary RNA-targeted therapies with a specific focus on microRNAs, today announced that the company held a ...
miRagen Therapeutics, Inc. (MGEN) Q2 2020 Earnings Conference Call August 5, 2020 4:30 PM ET Company Participants Dan Ferry – Managing Director-LifeSci Advisors Bill Marshall – President and Chief Executive Officer Diana Escolar – Chief Medical Officer Jaso...
Miragen Therapeutics (NASDAQ: MGEN ) : Q2 GAAP EPS of -$0.12 beats by $0.05 . More news on: Miragen Therapeutics, Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Miragen Therapeutics Inc. Company Name:
MGEN Stock Symbol:
NASDAQ Market:
Miragen Therapeutics Inc. Website:
Jonathan Violin, Ph.D., M.B.A. appointed President, CEO and director Barrett Katz, M.D., M.B.A. joins Viridian as Chief Medical Officer Viridian is developing VRDN-001 and VRDN-002 for the treatment of thyroid eye disease Company recently licensed exc...
Company obtains exclusive rights to develop and commercialize antibody therapeutics targeting insulin-like growth factor-1 receptor (IGF-1R) using Xencor’s Xtend™ half-life extension technology miRagen expects to file an Investigational New Drug (IND) application for VRD...
Recently completed acquisition of Viridian Therapeutics, including an anti-IGF-1R monoclonal antibody, VRDN-001, for the potential treatment of thyroid eye disease (TED) Private placement financing proceeds of approximately $91 million positions miRagen to potentially advance mult...